Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
LRRC19 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IF, ICC, E |
|---|---|
| Primary Accession | Q9H756 |
| Other Accession | NP_075052, 12597641 |
| Reactivity | Human, Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | 42334 Da |
| Application Notes | LRRC19 antibody can be used for detection of LRRC19 by Western blot at 1 µg/mL. Antibody can also be used for immunocytochemistry starting at 2.5 µg/mL. For immunofluorescence start at 20 µg/mL. |
| Gene ID | 64922 |
|---|---|
| Target/Specificity | LRRC19; |
| Reconstitution & Storage | LRRC19 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Precautions | LRRC19 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | LRRC19 (HGNC:23379) |
|---|---|
| Function | Pathogen-recognition receptor which mediates the activation of TRAF2- and TRAF6 NF-kappa-B signaling pathways and induces the expression of pro-inflammatory cytokines (PubMed:19679103, PubMed:25026888). In kidney, prevents infection by uropathogenic bacteria by inducing the production of cytokines, chemokines and antimicrobial substances. In gut, involved in host-microbiota interactions, plays a critical role in promoting the recruitment of immune cells and intestinal inflammation (By similarity). |
| Cellular Location | Membrane; Single-pass type I membrane protein |
| Tissue Location | Expressed in renal collecting duct epithelial cells. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
LRRC19 Antibody: LRRC19 is a member of the extracellular leucine-rich repeat superfamily, a family of proteins that are thought to have diverse functions such as cell adhesion, signaling, and innate immunity. LRRC19 is closely related to the Toll-like receptors (TLRs), especially TLR3. LRRC19 does not contain a cytoplasmic Toll/IL-1 receptor (TIR) domain, but can activate NF-κB and induce the production of proinflammatory cytokines after stimulation with the TLR3 and other TLR ligands, suggesting that LRRC19 may play a role in the recognition and the response to certain pathogenic microorganisms. LRRC19 has also been suggested to be a potential biomarker for pancreatic tumor sensitivity to the anti-cancer, small molecule Src inhibitor AZD0530.
References
Dolan J, Walshe K, Alsbury S, et al. The extracellular leucine-rich repeat superfamily: a comparative survey and analysis of evolutionary relationships and expression patterns. BMC Genomics2007; 8:320.
Chai L, Dai L, Che Y, et al. LRRC19, a novel member of the leucine-rich repeat protein family, activates NF-kB and induces expression of proinflammatory cytokines. Biochem. Biophys. Res. Comm.2009; 388:543-8.
Rajeshkumar NV, Tan AC, De Oliveira E, et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin. Cancer Res.2009; 15:4138-46.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
